Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2025-04-03 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
首次公开发行部分限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the listing and circulation of restricted shares (限售股) following the company's initial public offering (IPO). It details the number of shares becoming tradable, the dates, shareholder commitments, and regulatory approvals. It does not contain financial statements or detailed financial performance data. The document is relatively short (2634 characters) and serves as an official notice about share circulation rather than a financial report or earnings release. This fits the category of Share Issue/Capital Change announcements, specifically about restricted shares becoming tradable after lock-up periods.
2025-04-03 Chinese
关于持股5%以上股东减持计划时间届满暨减持结果的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the completion of a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details the shareholder's initial holdings, the planned reduction, the actual reduction results, and confirms that the reduction plan period has ended. The content focuses on shareholding changes by a major shareholder and the results of that shareholding reduction plan. This matches the definition of a Major Shareholding Notification (MRQ), which involves notifications of changes in significant share ownership levels. The document is not a full financial report, earnings release, or regulatory filing, but a specific announcement about shareholding changes.
2025-03-25 Chinese
关于持股5%以上股东权益变动的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a change in shareholding by a shareholder holding more than 5% of the company's shares. It details the reduction in shares held by Chengdu Yingchuang Power Venture Capital Co., Ltd., including specific dates, share quantities, and percentages. The document explicitly states it is a "提示性公告" (prompting announcement) about the change in equity holdings exceeding 1%, which is a typical major shareholding notification. There is no financial data, no report attached or referenced as published, and no mention of other report types. Therefore, this fits the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, confirming it is not a full report or other filing type.
2025-03-05 Chinese
2024年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2024 年度业绩快报公告" which translates to "2024 Annual Performance Express Report Announcement." It contains preliminary financial data for the year 2024, including revenue, profit, and other financial metrics. The data is explicitly stated as preliminary and unaudited, with a disclaimer that the final audited data will be in the full annual report. The document is relatively short (1754 characters) and serves as an initial announcement of financial results rather than a comprehensive annual report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not the full Annual Report (10-K) or Interim Report (IR) because it lacks detailed financial statements and is preliminary. Therefore, the correct classification is Earnings Release (ER). FY 2024
2025-02-27 Chinese
关于持股5%以上股东权益变动的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement from a company regarding a change in shareholding by a shareholder holding more than 5% of the company's shares. It details the reduction in shares held by the shareholder, the percentage change, and confirms that this change does not affect control of the company. The document references regulatory requirements for disclosure of such changes and provides detailed shareholding data before and after the change. There is no financial report, earnings data, or management discussion. The content fits the definition of a Major Shareholding Notification, which involves notifying changes in significant share ownership levels crossing thresholds.
2025-02-21 Chinese
自愿披露关于HP515片中国临床试验完成首例受试者入组的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by a pharmaceutical company about the completion of the first subject enrollment in a clinical trial for a drug (HP515) targeting non-alcoholic steatohepatitis (NASH). It provides detailed information about the drug, the clinical trial phase, regulatory approvals, and potential impact on the company. The document is an announcement of a clinical trial milestone rather than a financial report, regulatory filing, or management discussion. It does not contain financial data, earnings, or governance information. It is not a report publication announcement since it is a substantive announcement about a clinical trial progress. Therefore, the document best fits the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-01-19 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.